Myocardial contrast echocardiography is a new method for evaluating myocardial perfusion. However, it relies on the marriage of two evolving technologies; ultrasound contrast agents and ultrasound imaging instrumentation. To date, these technologies have only been available to a limited number of researchers throughout the world. Within the next 12 months, both agents and specialised ultrasound instruments will be commercially available, making this new methodology open to widespread clinical application. Moreover, echocardiographic evaluation of myocardial perfusion should have a major role in the management of both chronic and acute ischaemic situations, myocardial infarction, and assessment of myocardial viability. This review examines the current and likely future status of both contrast agents and machines in this context. In addition, the probable clinical role of the methodology, as a potential replacement for nuclear techniques, is discussed
In patients with coronary artery disease the study of myocardial perfusion is of great clinical relevance and is currently investigated by nuclear medicine techniques. Nuclear cardiology, however, is limited by contamination risks, by a limited availability of the equipment, and by considerable expense. Furthermore, the current role of nuclear medicine in cardiology is mainly confined to stable patients, while acutely ill patients rarely benefit from the information regarding myocardial perfusion.
An alternative method of studying myocardial perfusion is echocardiography following the injection of ultrasound contrast agents directly into the coronary circulation. ' New contrast agents Left ventricular cavity opacification can be obtained in the majority of patients after venous injection of lung-crossing agents such as Albunex (MBI, USA)3 and Levovist (Schering AG, Germany).4 However, neither of these agents is able to opacify the myocardium consistently using conventional signal processing and imaging modalities. In an attempt to visualise myocardial perfusion by intravenous Albunex injection, Villaneuva et a15 injected dogs with a dose of this agent 10 times that previously used for diagnostic purposes. They selected microbubbles with a diameter larger than those used for conventional imaging and injected the contrast agent directly into the right atrial cavity. In addition, the animals were premedicated with dipyridamole (to increase the ratio between coronary blood flow and cardiac output) and, finally, the echocardiographic images were digitally subtracted and colour coded. Although this approach allowed myocardial perfusion to be visualised in experimental animals, it cannot be used in the clinical setting.
Recently, a new generation of ultrasound contrast agents has been produced characterised by a prolonged persistence in the circulation. This persistence is related to the shell stability and the gases contained in the microbubbles, which have a higher density than air and a low solubility in blood. As shown in fig 1, the echo contrast effect generated by an agent spontaneously declines over time. This spontaneous decay in contrast intensity resembles that of radioisotopes and is mainly caused by the diffusion of the gases from the microbubbles in the surrounding medium. Thus, the microbubbles containing gases with low solubility in blood are characterised by a prolonged persistence and in vivo stability.
A precursor of long persistence contrast agents is the agent EchoGen (Sonus Pharmaceutical, USA), which is based on dodecafluoropentane. This Figure 1 Spontaneous decay in echo contrast intensity. In this experiment the contrast agent SHU 454 (Echovist) was injected in a recirculatingflow model. After the equilibrium was reached, signal intensity declined because of the diffusion ofgases from the microbubbles in the surrounding medium. The decay half time of Echovist in saline corresponded to 68 seconds. IB2D, 3D integrated backscatter index. Figure 2 shows that myocardial contrast effect does reflect true myocardial perfusion. In this dog, the left circumflex coronary artery was cannulated and perfused via a bypass with blood taken from the femoral artery ( fig 3) ; a reservoir filled with blood was present in series in the bypassing circuit and delayed the arrival of blood in the circumflex perfusion territory. After intravenous contrast administration, the myocardium perfused by the left anterior descending and the right coronary artery early showed contrast enhancement (fig 2, left  panel) , while the myocardium perfused by the circumflex coronary artery showed a late contrast effect (fig 2, right panel) This means that, when exposed to an ultrasound field where the resonance frequency of the contrast microspheres lies within the bandwidth of transmitted ultrasound, the characteristics of the backscattered signal will be altered in some way. Contrast microspheres absorb energy at their resonant frequency and that absorbed energy is re-emitted at harmonics of the resonant frequency" (fig 4) . While contrast agents do cause an increase in backscattered ultrasound intensity at the fundamental frequency (centre frequency of the transducer), the increment in intensity over the signal reflected from myocardial tissue is relatively small. This can make it difficult to evaluate the presence of the agent within the tissue. However, by examining specifically the signal content at the resonant frequency or its harmonic (especially the 2nd harmonic), there is much greater difference in signal level between tissue alone and tissue plus contrast. This makes detection of the presence of the contrast agent and its distribution much easier to appreciate.
While the tissue signal at the 2nd harmonic, which is achieved by transmitting at one frequency and then selectively receiving at double that frequency, is relatively low, the contrast agent generates a high amplitude signal, which is easier to detect. This technology is relatively easy to implement, either by modification to transducer design or by using broadband width transducers and digital input filtering. It has been shown to demonstrate myocardial perfusion as well as perfusion in other organs such as liver and kidney following low volume intravenous injections.'5 It is unlikely that 2nd harmonic imaging is the final stage in the development of contrast agent imaging technology.
Recent studies have indicated that exposure of contrast microbubbles to diagnostic ultrasound fields results in their destruction. This clearly limits the potential effectiveness of ultrasound detection of perfusion. Methods to limit this phenomenon have been investigated including reducing the transducer output power, thereby decreasing spatial ultrasound intensity. Reductions in temporal ultrasound exposure may also be achieved by reconfiguring the echocardiography system so that intermittent rather than continuous imaging is performed.816 This means that only one frame of an echocardiographic image is generated every cardiac cycle (or every other cardiac cycle) rather than the normal imaging mode when approximately 30 frames per second are generated. By employing intermittent imaging, significant improvements in detection of myocardial perfusion have been demonstrated,'7 as destruction of contrast microspheres is considerably reduced and microspheres that are destroyed are usually replenished before the next frame is created. One limitation of this technique is that a real time image is no longer displayed, which may have limitations for temporal analysis and visual appreciation of contrast appearance and disappearance. Improvements in image processing and display technology are likely to be employed to overcome these limitations. However, it is also possible that the phenomenon of contrast microbubble destruction could be turned to advantage in the future, as contrast microbubbles could be used for drug delivery, using localised higher intensity ultrasound to destroy the microspheres and release a drug at desired sites. In addition, it may be possible to adjust ultrasound output power levels, so that contrast microspheres are destroyed at exactly the same rate that they are replenished, within a given myocardial bed. Myocardial perfusion, which was occurring at a rate higher than the destruction rate, would result in a gradual increase in segment intensity, whereas lower levels of perfusion would mean that more microbubbles were being destroyed than being replenished and so intensity would decrease. In theory, this would allow this phenomenon to be used for measuring myocardial perfusion.
These technologies are still very much in their infancy, however, many ultrasound instrument manufacturers are introducing harmonic imaging as a facility on their systems. In addition, quantitative software is now available Figure 6 Contrast echo images obtained by the injection ofAlbunex into the left coronaty artery of a patient, both at baseline and after low dose dipyridamole infusion.
that allows analysis of the changes in 2nd harmonic (or other frequency characteristic) amplitudes before, during, and after contrast administration. Software that performs digital subtraction and colour coding on harmonic images is also, being generated and this should create colour coded perfusion images, similar to those obtained by nuclear medicine studies. Pseudo-colour maps are often used to enhance the detection of spontaneous echo contrast in the left atrial cavity or appendage and such specific display modalities might favour the detection of low concentrations of contrast agent. Although no studies have so far compared grey scale with colour images in the detection of myocardial perfusion abnormalities, it is expected that colour coded images could allow a better detection of myocardial contrast enhancement.
A further advancement might be the use of so called functional images,18 where the colour represents the value of a functional parameter ( fig 5) . Each of these two images derives from the analysis of a series of frames and the colours represent the time from contrast injection into the aortic root up to myocardial contrast appearance. Under baseline conditions, the myocardium appears homogeneously red, while it turns toward yellow in the area perfused by a stenotic left circumflex coronary artery because of a delay in myocardial contrast appearance. Although these imaging modalities may favour the detection and localisation of myocardial perfusion abnormalities, it is not clear what the best parameter will be to study myocardial perfusion by intravenous contrast echocardiography. In patients with acute infarction, the end points of contrast echocardiography should be to detect myocardial perfusion abnormalities, to quantify the spatial extent of these abnormalities, to establish the occurrence of myocardial reperfusion, and thus to predict the late recovery of left ventricular function.
In patients with previous infarction, contrast echocardiography should provide indices of myocardial viability, based on the hypothesis that myocardial echo contrast effect reflects microvascular integrity and thus viability. '9 Finally, contrast echocardiography should be compared with stress echocardiography with the end point of detecting myocardial ischaemia or viability. 20 An example of combined stress and contrast echocardiography is shown in fig 6, where Albunex was injected into the left coronary artery of a patient with previous infarction both at baseline and after intravenous dipyridamole infusion.
Conclusion
After the initial observation that it was possible to study myocardial perfusion by echocardiography, following injection of contrast agents into the coronary circulation, different investigators, pharmaceutical, and instrument companies have contributed towards a progressive advancement of knowledge in this field. Once the new generation of echo contrast agents and scanners are available, an acceleration in this process can be expected. The combination of these efforts will provide a non-invasive, non-nuclear assessment of myocardial perfusion, preserving the high spatial and temporal resolution of ultrasound, in addition, being available in real time in a number of different clinical arena.
